NEURO-CLARITY Study

Study Overview

An open-label study investigating a potential treatment for early-stage cognitive decline. Participants will receive the study medication and undergo regular cognitive assessments over the study period.

Inclusion Criteria

• ✓Adults aged 55-80 years
• ✓Mild cognitive impairment diagnosis
• ✓MMSE score between 20-26
• ✓Caregiver available for study visits

Exclusion Criteria

• ✗Alzheimer's disease diagnosis
• ✗Current use of cholinesterase inhibitors
• ✗History of stroke within past year
• ✗Severe depression